Latest Clinical Practice Guideline for IgA Vasculitis
The most recent comprehensive clinical practice guideline specifically for IgA vasculitis (IgAV) is the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV), published in 2025 1. Additionally, evidence-based guidelines for adult-onset IgA vasculitis were published in Nature Reviews Rheumatology in 2026 2.
Key Guideline Resources
Primary Guidelines
KDIGO 2025 IgAN and IgAV Guideline 1: This represents the most authoritative international guideline, providing comprehensive management recommendations for both IgA nephropathy and IgA vasculitis. The executive summary was published in Kidney International in 2025.
European Expert Guidelines (2026) 2: These evidence-based, multidisciplinary guidelines specifically address adult-onset IgAV, comprising 14 recommendation statements developed through systematic literature review and expert consensus by leading European specialists.
Supplementary Guidelines
IPNA Pediatric Recommendations (2025) 3: The International Pediatric Nephrology Association published clinical practice recommendations specifically for children with IgA nephropathy and IgA vasculitis nephritis.
UK National Recommendations (2024) 4: National guidelines for children and young people with IgA vasculitis, endorsed by the UK Kidney Association and Royal College of Paediatrics and Child Health, providing 21 graded recommendations across multiple clinical domains.
Chinese Guidelines (2025) 5: Clinical practice guidelines tailored to Chinese patients with IgAN and IgA vasculitis-associated nephritis.
Important Clinical Context
Disease Recognition
IgA vasculitis and IgA nephropathy are increasingly understood as part of a disease spectrum sharing common pathogenic mechanisms involving galactose-deficient IgA1 6. While IgAN represents kidney-limited disease, IgAV is the systemic manifestation affecting skin, gastrointestinal tract, kidneys, and joints 2.
Adult vs. Pediatric Disease
A critical distinction exists between adult and pediatric IgAV 2, 7:
- Adult-onset IgAV is considerably less frequent than childhood disease but carries a significantly poorer prognosis
- Adults experience more severe disease courses with higher rates of renal and gastrointestinal involvement
- Greater risk of long-term morbidity and chronic kidney disease progression
- Diagnostic challenges persist due to lack of validated adult-specific criteria
Management Challenges
The treatment of adult-onset IgAV remains limited by 2:
- Paucity of high-quality clinical trials
- Lack of standardized therapeutic approaches
- Absence of IgAV-specific disease activity scores
- Most existing criteria developed for pediatric populations
Rapidly Progressive Disease
For patients with rapidly progressive IgA vasculitis nephritis (≥50% decline in eGFR over ≤3 months with extensive glomerular crescent formation), treatment should follow the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis, using cyclophosphamide and systemic glucocorticoids 1. There is insufficient evidence supporting rituximab for rapidly progressive IgAN.
Prognostic Considerations
Short-term outcomes are primarily determined by gastrointestinal complications, while kidney involvement and chronic kidney disease progression are the major determinants of long-term prognosis 2. Consistent prognostic indicators for adverse outcomes include renal and gastrointestinal involvement, older age, and medical comorbidities 7.